GlaxoSmithKline granted FDA approval for drug to treat multiple myeloma

GlaxoSmithKline said the treatment was granted an accelerated approval based on patient response rate in clinical trials.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.